53 related articles for article (PubMed ID: 24201803)
1. Nuclear NHERF1 expression as a prognostic marker in breast cancer.
Paradiso A; Scarpi E; Malfettone A; Addati T; Giotta F; Simone G; Amadori D; Mangia A
Cell Death Dis; 2013 Nov; 4(11):e904. PubMed ID: 24201803
[TBL] [Abstract][Full Text] [Related]
2. Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells.
Pan Y; Weinman EJ; Dai JL
Breast Cancer Res; 2008; 10(1):R5. PubMed ID: 18190691
[TBL] [Abstract][Full Text] [Related]
3. NHERF1/EBP50 in Breast Cancer: Clinical Perspectives.
Bellizzi A; Malfettone A; Cardone RA; Mangia A
Breast Care (Basel); 2010; 5(2):86-90. PubMed ID: 21048827
[TBL] [Abstract][Full Text] [Related]
4. A molecular switch for the orientation of epithelial cell polarization.
Bryant DM; Roignot J; Datta A; Overeem AW; Kim M; Yu W; Peng X; Eastburn DJ; Ewald AJ; Werb Z; Mostov KE
Dev Cell; 2014 Oct; 31(2):171-87. PubMed ID: 25307480
[TBL] [Abstract][Full Text] [Related]
5. Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer.
Crocamo S; Binato R; Dos Santos EC; de Paula B; Abdelhay E
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555156
[TBL] [Abstract][Full Text] [Related]
6. HAS2-Ezrin-ER axis plays a role in acquired antiestrogen resistance of ER-positive breast cancer.
Sun X; Tang F; Guo Q; Liu Y; He Y; Du Y; Gao F; Zhang G; Yang C
Front Pharmacol; 2022; 13():1031487. PubMed ID: 36386154
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiological role of ion channels and transporters in HER2-positive breast cancer.
Zhou Z; Zhang C; Ma Z; Wang H; Tuo B; Cheng X; Liu X; Li T
Cancer Gene Ther; 2022 Aug; 29(8-9):1097-1104. PubMed ID: 34997219
[TBL] [Abstract][Full Text] [Related]
8. MINDIN Exerts Protumorigenic Actions on Primary Prostate Tumors via Downregulation of the Scaffold Protein NHERF-1.
Álvarez-Carrión L; Gutiérrez-Rojas I; Rodríguez-Ramos MR; Ardura JA; Alonso V
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33498862
[TBL] [Abstract][Full Text] [Related]
9. Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002.
Diotaiuti S; De Summa S; Altieri R; Dantona C; Tommasi S; Di Gennaro M; Rubini G; Pastena MI; Argentiero A; Zito FA; Silvestris N; Paradiso AV
Oncol Lett; 2020 Sep; 20(3):2469-2476. PubMed ID: 32782565
[TBL] [Abstract][Full Text] [Related]
10. Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients.
Schirosi L; Saponaro C; Giotta F; Popescu O; Pastena MI; Scarpi E; Mangia A
Transl Oncol; 2020 Feb; 13(2):186-192. PubMed ID: 31865181
[TBL] [Abstract][Full Text] [Related]
11. Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?
Mangia A; Saponaro C; Vagheggini A; Opinto G; Centonze M; Vicenti C; Popescu O; Pastena M; Giotta F; Silvestris N
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540486
[TBL] [Abstract][Full Text] [Related]
12. Cardamonin inhibits breast cancer growth by repressing HIF-1α-dependent metabolic reprogramming.
Jin J; Qiu S; Wang P; Liang X; Huang F; Wu H; Zhang B; Zhang W; Tian X; Xu R; Shi H; Wu X
J Exp Clin Cancer Res; 2019 Aug; 38(1):377. PubMed ID: 31455352
[TBL] [Abstract][Full Text] [Related]
13. Independent Negative Prognostic Role of TCF1 Expression within the Wnt/β-Catenin Signaling Pathway in Primary Breast Cancer Patients.
Saponaro C; Scarpi E; Zito FA; Giotta F; Silvestris N; Mangia A
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336689
[TBL] [Abstract][Full Text] [Related]
14. Epithelial differentiation with microlumen formation in meningioma: diagnostic utility of NHERF1/EBP50 immunohistochemistry.
Georgescu MM; Olar A; Mobley BC; Faust PL; Raisanen JM
Oncotarget; 2018 Jun; 9(47):28652-28665. PubMed ID: 29983887
[TBL] [Abstract][Full Text] [Related]
15. Ezrin-Radixin-Moesin Binding Phosphoprotein 50: A Potential Novel Biomarker in Human Papilloma Virus-Associated Head and Neck Squamous Cell Carcinomas.
Shankar A; Crouch DH; Macluskey M
Head Neck Pathol; 2019 Jun; 13(2):188-197. PubMed ID: 29846905
[TBL] [Abstract][Full Text] [Related]
16. NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma.
Saponaro C; Vagheggini A; Scarpi E; Centonze M; Catacchio I; Popescu O; Pastena MI; Giotta F; Silvestris N; Mangia A
J Exp Clin Cancer Res; 2018 May; 37(1):96. PubMed ID: 29716631
[TBL] [Abstract][Full Text] [Related]
17. NHERF1 Between Promises and Hopes: Overview on Cancer and Prospective Openings.
Centonze M; Saponaro C; Mangia A
Transl Oncol; 2018 Apr; 11(2):374-390. PubMed ID: 29455084
[TBL] [Abstract][Full Text] [Related]
18. NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
Mangia A; Scarpi E; Partipilo G; Schirosi L; Opinto G; Giotta F; Simone G
Oncotarget; 2017 Sep; 8(39):65730-65742. PubMed ID: 29029467
[TBL] [Abstract][Full Text] [Related]
19. Comment on 'Renewed interest in the progesterone receptor in breast cancer'.
Simone G; Diotaiuti S; Digennaro M; Sambiasi D; De Summa S; Tommasi S; Altieri R; Mangia A; Dantona C; Paradiso A
Br J Cancer; 2017 Jul; 117(2):e1. PubMed ID: 28399113
[No Abstract] [Full Text] [Related]
20. The scaffolding protein NHERF1 regulates the stability and activity of the tyrosine kinase HER2.
Jeong J; VanHouten JN; Kim W; Dann P; Sullivan C; Choi J; Sneddon WB; Friedman PA; Wysolmerski JJ
J Biol Chem; 2017 Apr; 292(16):6555-6568. PubMed ID: 28235801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
